Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 7, Issue 4, 2012, Pages 737-743

  Lang Lazdunski, Loïc ^a   Bille, Andrea ^a   Lal, Rohit ^a   Cane, Paul ^b   McLean, Emma ^b   Landau, David ^a   Steele, Jeremy ^c   Spicer, James ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

Extrapleural pneumonectomy; Malignant pleural mesothelioma; Pleurectomy

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE; PEMETREXED; SORAFENIB;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DECORTICATION; EXTRAPLEURAL PNEUMONECTOMY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MORTALITY; PLEURA MESOTHELIOMA; PLEURECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

EID: 84858789724     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824ab6c5     Document Type: Article

References (28)

1. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-672. (Pubitemid 29046253)
2. Muers MF, Stephens RJ, Fisher P, et al. MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:1685-1694. (Pubitemid 351671885)
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644. (Pubitemid 46606305)
4. Maziak DE, Gagliardi A, Haynes AE, Mackay JA, Evans WK. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005;48:157-169.
5. Sugarbaker DJ, Flores RM, Jacklitsch M, et al. Resection margins, extrapleural nodal status and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63.
6. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991;102:1-9.
7. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-3013.
8. Weder W, Stahel RA, Bernhard J, et al.; Swiss Group for Clinical Cancer Research. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196-1202. (Pubitemid 47244366)
9. de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:1413-1418.
10. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685-92; discussion 1692.
11. Treasure T, Waller D, Tan C, et al. The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study. J Thorac Oncol 2009;4:1254-1258.
12. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004;128:138-146. (Pubitemid 38881208)
13. Allen AM, Czerminska M, Jänne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006;65:640-645. (Pubitemid 43795851)
14. Jänne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin 2004;14:567-573. (Pubitemid 39314491)
15. Wanebo HJ, Martini N, Melamed MR, Hilaris B, Beattie EJ Jr. Pleural mesothelioma. Cancer 1976;38:2481-2488. (Pubitemid 8015884)
16. Neragi-Miandoab S, Richards WG, Sugarbaker DJ. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg 2008;6:293-297.
17. Lee TT, Everett DL, Shu HK, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002;124:1183-1189. (Pubitemid 35417006)
18. Bölükbas S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J. Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. Lung Cancer 2011;71:75-81.
19. Treasure T, Lang-Lazdunski L, Waller D, et al. The Mesothelioma and Radical Surgery (MARS) randomized controlled trial comparing extra-pleural pneumonectomy (EPP) with no EPP in patients with malignant pleural mesothelioma. Lancet Oncol 2011;12:763-772.
20. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995;108:754-758.
21. Van Schil PE, Baas P, Gaafar R, et al.; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362-1369.
22. Cao C, Yan TD, Bannon PG, McCaughan BC. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010;5:1692-1703.
23. Flores, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-626.
24. Nakas A, Trousse DS, Martin-Ucar AE, Waller DA. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 2008; 34:886-891.
25. Weder W, Stahel RA, Baas P, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011;12:1093-4; author reply 1094.
26. Patel A, Anraku M, Darling GE, et al. Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies. J Thorac Cardiovasc Surg 2009;138:843-848.
27. Cameron RB. Extrapleural pneumonectomy is the preferred surgical management in the multimodality therapy of pleural mesothelioma: con argument. Ann Surg Oncol 2007;14:1249-1253. (Pubitemid 46536804)
28. Rusch VW. The MARS trial: resolution of the surgical controversies in mesothelioma? J Thorac Oncol 2009;4:1189-1191.